Prograf + Advagraf
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
de Novo Liver Transplant Subjects
Conditions
de Novo Liver Transplant Subjects
Trial Timeline
Jan 30, 2013 → Jan 3, 2017
NCT ID
NCT01882322About Prograf + Advagraf
Prograf + Advagraf is a approved stage product being developed by Astellas Pharma for de Novo Liver Transplant Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT01882322. Target conditions include de Novo Liver Transplant Subjects.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01882322 | Approved | Completed |
| NCT01839929 | Approved | Completed |
Competing Products
19 competing products in de Novo Liver Transplant Subjects